Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis

Noah Lechtzin, Marisa E. Hilliard, Maureen Horton

Research output: Contribution to journalArticle

Abstract

Background: Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF. Methods: The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF. Participants were adults with IPF and chronic cough. A cough visual analog scale (VAS) and the St. George's Respiratory Questionnaire (SGRQ) were administered to establish concurrent validity of the CQLQ. Results: Internal consistency was high (Cronbach α > .70) for the CQLQ total and four of six subscale scores. The CQLQ total score demonstrated concurrent validity through significant correlations with scores on the cough VAS and SGRQ total and subscale scores (r range, 0.63-0.81; P

Original languageEnglish (US)
Pages (from-to)1745-1749
Number of pages5
JournalChest
Volume143
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Idiopathic Pulmonary Fibrosis
Cough
Quality of Life
Visual Analog Scale
Surveys and Questionnaires
Thalidomide
Reproducibility of Results
Cross-Over Studies
Disease Progression

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis. / Lechtzin, Noah; Hilliard, Marisa E.; Horton, Maureen.

In: Chest, Vol. 143, No. 6, 06.2013, p. 1745-1749.

Research output: Contribution to journalArticle

@article{479652f8c4bc41ecbee4ffdad392281f,
title = "Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis",
abstract = "Background: Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF. Methods: The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF. Participants were adults with IPF and chronic cough. A cough visual analog scale (VAS) and the St. George's Respiratory Questionnaire (SGRQ) were administered to establish concurrent validity of the CQLQ. Results: Internal consistency was high (Cronbach α > .70) for the CQLQ total and four of six subscale scores. The CQLQ total score demonstrated concurrent validity through significant correlations with scores on the cough VAS and SGRQ total and subscale scores (r range, 0.63-0.81; P",
author = "Noah Lechtzin and Hilliard, {Marisa E.} and Maureen Horton",
year = "2013",
month = "6",
doi = "10.1378/chest.12-2870",
language = "English (US)",
volume = "143",
pages = "1745--1749",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis

AU - Lechtzin, Noah

AU - Hilliard, Marisa E.

AU - Horton, Maureen

PY - 2013/6

Y1 - 2013/6

N2 - Background: Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF. Methods: The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF. Participants were adults with IPF and chronic cough. A cough visual analog scale (VAS) and the St. George's Respiratory Questionnaire (SGRQ) were administered to establish concurrent validity of the CQLQ. Results: Internal consistency was high (Cronbach α > .70) for the CQLQ total and four of six subscale scores. The CQLQ total score demonstrated concurrent validity through significant correlations with scores on the cough VAS and SGRQ total and subscale scores (r range, 0.63-0.81; P

AB - Background: Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF. Methods: The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF. Participants were adults with IPF and chronic cough. A cough visual analog scale (VAS) and the St. George's Respiratory Questionnaire (SGRQ) were administered to establish concurrent validity of the CQLQ. Results: Internal consistency was high (Cronbach α > .70) for the CQLQ total and four of six subscale scores. The CQLQ total score demonstrated concurrent validity through significant correlations with scores on the cough VAS and SGRQ total and subscale scores (r range, 0.63-0.81; P

UR - http://www.scopus.com/inward/record.url?scp=84878529210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878529210&partnerID=8YFLogxK

U2 - 10.1378/chest.12-2870

DO - 10.1378/chest.12-2870

M3 - Article

C2 - 23519393

AN - SCOPUS:84878529210

VL - 143

SP - 1745

EP - 1749

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -